Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is FLUOXETINE HYDROCHLORIDE USP, with a corresponding US DMF Number 14253.
Remarkably, this DMF maintains an Active status since its submission on June 29, 1999, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 31, 2013, and payment made on July 19, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II